Chris Wilkins

Chris Wilkins

Auto-generated profile, based on publicly available information

Chris Wilkins

SHORE & Whariki Research Centre, College of Health, Massey University, New Zealand

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2015 in International Journal of Drug Policy
Verified
Journal Article
Closed access
MBMonica J. Barratt
Monica J. Barratt
GPGary Potter
Gary Potter
MWMarije Wouters
Marije Wouters
CWChris Wilkins
Chris Wilkins
BWBernd Werse
Bernd Werse
TBThomas Blok
Thomas Blok

1 March 2019 in Science of The Total Environment
Verified
Journal Article
Closed access
RKRahul Kumar
Rahul Kumar
BTBenjamin J. Tscharke
Benjamin J. Tscharke
JOJake O'Brien
Jake O'Brien
JMJochen F. Mueller
Jochen F. Mueller
CWChris Wilkins
Chris Wilkins
LPLokesh P. Padhye
Lokesh P. Padhye


1 April 2018 in International Journal of Drug Policy
Verified
Journal Article
Closed access
VBVendula Belackova
Vendula Belackova
CWChris Wilkins
Chris Wilkins

14 June 2005 in Addiction
Verified
Journal Article
Closed access
PDF file
CWChris Wilkins
Chris Wilkins
JRJames L. Reilly
James L. Reilly
SCSally Casswell
Sally Casswell

1 November 2008 in Drug and Alcohol Review
Verified
Journal Article
Closed access
PDF file
CWChris Wilkins
Chris Wilkins
PSPaul Sweetsur
Paul Sweetsur
MGMelissa Girling
Melissa Girling
Introduction and Aims. A large legal market for party pills containing benzylpiperazine (BZP) and trifluoromethylphenylpiperazine (TFMPP) developed in New Zealand after 2004. The use of these party pills has been associated with adverse health effects. The purpose of this paper was to assess a general population sample of party pill users to investigate the relationship between (1) patterns of use of BZP/TFMPP party pills and concurrent use of other drug types, and (2) adverse side effects from BZP/TFMPP party pill use. Design. A national household survey of the use of BZP/TFMPP party pills was conducted using a computer‐assisted telephone interviewing (CATI) facility. The quantity of BZP and TFMPP in each brand of party pill was obtained from the National Poisons Centre. Multiple logistic regression analysis was used to identify independent predictors of having experienced adverse side effects from party pills. Results. The mean quantity of BZP/TFMPP taken on an occasion of greatest use was 533 mg (median 400 mg, range 43 – 2500 mg). Being female, using cannabis and other drugs concurrently with BZP/TFMPP party pills, taking large quantities of party pills in a single session and taking 5‐hydroxytryptophan (5‐HTP) recovery pills at the same time as party pills were independent predictors of having experienced an adverse problem from party pills. Conclusions. Females may be at greater risk of experiencing problems from BZP/TFMPP party pills due to their smaller physical size. Taking 5‐HTP ‘recovery’ pills with party pills may increase the risk of adverse effects as both substances increase users' levels of serotonin.